RioDerm-001 is under clinical development by Rion and currently in Phase II for Diabetic Foot Ulcers.
SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Solid Tumor.
L and J-HZ is under clinical development by L&J Bio and currently in Phase I for Herpes Zoster (Shingles).
RM-191A is under clinical development by RR MedSciences and currently in Phase II for Neuropathic Pain (Neuralgia).
CB-11 is under clinical development by Cellebrain and currently in Phase I for Glioblastoma Multiforme (GBM).
Development of autoimmune disease was more common in patients with surgical remission of Cushing’s disease than in those with surgically treated nonfunctioning pituitary adenomas (NFPAs),
Osude is a cardiology fellow. The U.S. kicked off its 60th annual American Heart Month with the sobering news that Black women who have high
No patterns of long-term or increasing use of opioids were identified within 3 years among opioid-naive children with sickle cell disease (SCD) who were prescribed
Niacin metabolism was associated with incident major adverse cardiovascular events (MACE) and may be linked to the pathogenesis of heart disease via inflammatory pathways, researchers
Jeremy Faust is editor-in-chief of , an emergency medicine physician at Brigham and Women’s Hospital in Boston, and a public health researcher. He is author